FDA grants second approval under new expedited-review pilot program
Merck's Keytruda marks the second label expansion, after Novartis' Kisqali, under Real-Time Oncology Review program.
Merck's Keytruda marks the second label expansion, after Novartis' Kisqali, under Real-Time Oncology Review program.